Sunesis Pharmaceuticals (NASDAQ:SNSS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Thursday.

According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “

SNSS has been the topic of several other research reports. Cantor Fitzgerald set a $3.00 price target on shares of Sunesis Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, December 11th. UBS Group began coverage on shares of Sunesis Pharmaceuticals in a research note on Monday, November 20th. They set an “outperform” rating on the stock. Oppenheimer began coverage on shares of Sunesis Pharmaceuticals in a research note on Tuesday, November 21st. They set an “outperform” rating and a $7.00 price target on the stock. ValuEngine raised shares of Sunesis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, February 7th. Finally, Wells Fargo & Co raised shares of Sunesis Pharmaceuticals from a “market perform” rating to an “outperform” rating and dropped their price target for the stock from $2.86 to $2.48 in a research note on Monday, December 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $3.75.

Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $6.02 on Thursday. Sunesis Pharmaceuticals has a one year low of $1.82 and a one year high of $6.24. The stock has a market cap of $201.72, a price-to-earnings ratio of -3.44 and a beta of 1.71. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.

A number of institutional investors have recently added to or reduced their stakes in SNSS. BlackRock Inc. increased its position in shares of Sunesis Pharmaceuticals by 9.5% in the 4th quarter. BlackRock Inc. now owns 130,573 shares of the biopharmaceutical company’s stock worth $482,000 after purchasing an additional 11,351 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Sunesis Pharmaceuticals by 77.4% in the 2nd quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 18,254 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sunesis Pharmaceuticals by 4.1% in the 2nd quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock worth $1,635,000 after purchasing an additional 23,819 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Sunesis Pharmaceuticals by 105.2% in the 4th quarter. Geode Capital Management LLC now owns 125,489 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 64,343 shares during the last quarter. Finally, Virtu KCG Holdings LLC bought a new stake in shares of Sunesis Pharmaceuticals in the 2nd quarter worth about $208,000. 39.46% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Sunesis Pharmaceuticals (SNSS) Rating Lowered to Sell at Zacks Investment Research” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/02/15/sunesis-pharmaceuticals-snss-rating-lowered-to-sell-at-zacks-investment-research-2.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Get a free copy of the Zacks research report on Sunesis Pharmaceuticals (SNSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.